You are here

Orally-Disintegrating Clonazepam Tablets Approved by FDA

SPRING VALLEY, N.Y., Aug. 3 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE:PRX) today announced that its wholly-owned subsidiary, Kali Laboratories, Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for clonazepam orally disintegrating tablets (ODT). Par's clonazepam ODT is the first generic version of the anticonvulsant Klonopin(R) Wafers. Annual U.S. sales of Klonopin(R) Wafers are approximately $18 million. Par will begin shipping the product immediately.

Source: Par Pharmaceutical Companies

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs